Watts Daniel T, Moosa Aliabbas, Elahi Zain, Palmer Antony J R, Rodriguez-Merchan E Carlos
University of Oxford NHS Foundation Trust. Nuffield Orthopaedic Centre, Windmill Rd, Oxford, OX3 7LD, UK.
University of Oxford NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK.
Arch Bone Jt Surg. 2022 Jun;10(6):470-479. doi: 10.22038/ABJS.2021.55790.2778.
This study compares the outcomes of patients undergoing total ankle arthroplasty (TAA) and tibiotalar fusion (ankle arthrodesis) in patients with end-stage osteoarthritis. The primary outcome assessed was Patient Reported Outcome Measures (PROMS); secondary outcomes included the incidence of revision, re-operation, and complications.
A systematic review of studies examining the outcomes of patients undergoing TAA and/or tibiotalar fusion from 2006 to 2020 was conducted. Individual cohort studies and randomized control trials were included. Outcomes were assessed at two and five years.
21 studies were included: 16 arthroplasty (2,016 patients) and 5 arthrodesis (256 patients) studies. No significant difference in PROMS was evident two years post-surgery - American Orthopaedic Foot and Ankle Society (AOFAS) scores were 78.8 (95% CI-confidence interval: 76.6-80.8; n=1548) and 80.8 (95% CI: 80.1-81.5; n=206 patients) for the arthroplasty and arthrodesis groups respectively. Two years post-surgery the revision rates for the arthroplasty and arthrodesis groups were similar - 3.5% (n=9) and 3.7% (n=61) respectively (OR-odds ratio: 1.05; 95% CI: 0.51-2.13); however, the re-operation rate was 2.5 times higher for the arthroplasty group (12.2%) in comparison to the arthrodesis group (5.1%) (OR: 2.57; 95% CI: 1.43-4.62). Documented complications in the arthroplasty group were half those documented in the arthrodesis group two years post-surgery (OR: 0.53; 95% CI: 0.37-0.77). No arthrodesis studies were found which contained mean 5-year follow-up data within the study period.
Despite recent developments in TAA design, we found no clear evidence as to their superiority over ankle arthrodesis when considering patient outcomes two years postoperatively. However, this conclusion could be debatable in some types of patients such as diabetic patients, posttraumatic patients and patients with stiff hindfoot and midfoot.
本研究比较了终末期骨关节炎患者接受全踝关节置换术(TAA)和胫距关节融合术(踝关节融合术)的治疗效果。评估的主要结果是患者报告的结局指标(PROMS);次要结果包括翻修、再次手术和并发症的发生率。
对2006年至2020年期间研究TAA和/或胫距关节融合术患者结局的研究进行系统综述。纳入了个体队列研究和随机对照试验。在两年和五年时评估结局。
纳入21项研究:16项关节置换术(2016例患者)和5项关节融合术(256例患者)研究。术后两年PROMS无显著差异——关节置换术组和关节融合术组的美国矫形足踝协会(AOFAS)评分分别为78.8(95%CI-置信区间:76.6-80.8;n=1548)和80.8(95%CI:80.1-81.5;n=206例患者)。术后两年,关节置换术组和关节融合术组的翻修率相似——分别为3.5%(n=9)和3.7%(n=61)(OR-优势比:1.05;95%CI:0.51-2.13);然而,关节置换术组的再次手术率比关节融合术组高2.5倍(12.2%对5.1%)(OR:2.57;95%CI:1.43-4.62)。术后两年,关节置换术组记录的并发症是关节融合术组的一半(OR:0.53;95%CI:0.37-0.77)。在研究期间未发现包含平均5年随访数据本研究比较了终末期骨关节炎患者接受全踝关节置换术(TAA)和胫距关节融合术(踝关节融合术)的治疗效果。评估的主要结果是患者报告的结局指标(PROMS);次要结果包括翻修、再次手术和并发症的发生率。
对2006年至2020年期间研究TAA和/或胫距关节融合术患者结局的研究进行系统综述。纳入了个体队列研究和随机对照试验。在两年和五年时评估结局。
纳入21项研究:16项关节置换术(2016例患者)和5项关节融合术(256例患者)研究。术后两年PROMS无显著差异——关节置换术组和关节融合术组的美国矫形足踝协会(AOFAS)评分分别为78.8(95%CI-置信区间:76.6-80.8;n=1548)和80.8(95%CI:80.1-81.5;n=206例患者)。术后两年,关节置换术组和关节融合术组的翻修率相似——分别为3.5%(n=9)和3.7%(n=61)(OR-优势比:1.05;95%CI:0.51-2.13);然而,关节置换术组的再次手术率比关节融合术组高2.5倍(12.2%对5.1%)(OR:2.57;95%CI:1.43-4.62)。术后两年,关节置换术组记录的并发症是关节融合术组的一半(OR:0.53;95%CI:0.37-0.77)。在研究期间未发现包含平均5年随访数据的关节融合术研究。
尽管TAA设计最近有所发展,但在考虑术后两年的患者结局时,我们没有发现明确证据表明其优于踝关节融合术。然而,在某些类型的患者中,如糖尿病患者、创伤后患者以及后足和中足僵硬的患者,这一结论可能存在争议。 的关节融合术研究。
尽管TAA设计最近有所发展,但在考虑术后两年的患者结局时,我们没有发现明确证据表明其优于踝关节融合术。然而,在某些类型的患者中,如糖尿病患者、创伤后患者以及后足和中足僵硬的患者,这一结论可能存在争议。